| 147.48 -3.1 (-2.06%) | 09-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 180.62 |
1-year : | 201.02 |
| Resists | First : | 154.64 |
Second : | 172.11 |
| Pivot price | 146.52  |
|||
| Supports | First : | 126.4 |
Second : | 105.16 |
| MAs | MA(5) : | 148.64 |
MA(20) : | 146.01 |
| MA(100) : | 157.6 |
MA(250) : | 232.78 |
|
| MACD | MACD : | -1.5 |
Signal : | -2.4 |
| %K %D | K(14,3) : | 61.8 |
D(3) : | 61.8 |
| RSI | RSI(14): 47.8 |
|||
| 52-week | High : | 354.88 | Low : | 126.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PODD ] has closed below upper band by 42.2%. Bollinger Bands are 55.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 150.75 - 151.48 | 151.48 - 152.21 |
| Low: | 143.28 - 144.19 | 144.19 - 145.09 |
| Close: | 145.78 - 147.24 | 147.24 - 148.67 |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Mon, 07 Sep 2026
Insulet Corporation (PODD) Investor Outlook: Analyzing the 16.56% Potential Upside in the Healthcare Sector - DirectorsTalk Interviews
Fri, 04 Sep 2026
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report? - Yahoo Finance
Thu, 03 Sep 2026
Unpacking Q2 Earnings: Insulet (NASDAQ:PODD) In The Context Of Other Patient Monitoring Stocks - Yahoo Finance
Sat, 29 Aug 2026
Insulet Corporation: Strong Growth Meets A New Execution Problem (NASDAQ:PODD) - Seeking Alpha
Thu, 20 Aug 2026
INSULET CORPORATION (PODD) SHAREHOLDER ALERT Bernstein - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 69 (M) |
| Shares Float | 69 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 107.3 (%) |
| Shares Short | 3,700 (K) |
| Shares Short P.Month | 4,650 (K) |
| EPS | 5.34 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.51 |
| Profit Margin | 12.2 % |
| Operating Margin | 16.1 % |
| Return on Assets (ttm) | 9.7 % |
| Return on Equity (ttm) | 26 % |
| Qtrly Rev. Growth | 23.5 % |
| Gross Profit (p.s.) | 31.29 |
| Sales Per Share | 43.97 |
| EBITDA (p.s.) | 8.86 |
| Qtrly Earnings Growth | 328.6 % |
| Operating Cash Flow | 511 (M) |
| Levered Free Cash Flow | 237 (M) |
| PE Ratio | 27.61 |
| PEG Ratio | 1.1 |
| Price to Book value | 7.19 |
| Price to Sales | 3.35 |
| Price to Cash Flow | 20 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|